


Is early joint damage acceptable in today's RA patient?

The majority of patients with Rheumatoid Arthritis will suffer erosive joint damage within 2 years of symptom onset offering a relatively narrow window of opportunity when disease modifying treatment can achieve most.¹

Today, our potential to suppress early joint damage in RA is highlighted by the results of a recent trial.² In this double-blind, randomised study in patients of median disease duration less than 9 months a significant slowing of joint damage was evident with Salazopyrin EN-tabs compared with hydroxychloroquine at 24 and 48 weeks.² Furthermore, the difference was still significant at 3-year follow-up.³ In the words of the authors, "the first blow is half the battle".³

Radiographic progression in patients treated with Salazopyrin EN-tabs or hydroxychloroquine.^{2,3}



When NSAIDs alone fail to preserve function and mobility

Salazopyrin® EN-tabs

enteric coated sulphasalazine

Today's choice to preserve tomorrow's lifestyle.

Abbreviated Prescribing Information

Presentation: Yellow enteric coated tablets, logo on one side, containing sulphasalazine 0.5g. Uses: Rheumatoid Arthritis unresponsive to NSAIDs. Dose: Do not break tablets. Adults/Elderly: 0.5g/day for a week, dose increasing to 0.5g twice weekly to a maximum of 3g/day in divided doses. Children: no recommendation. Contra-indications: Sulphonamide or salicylate sensitivity. Infants under 2 years of age. Precautions: Monthly blood checks and LFTs for 3 months. Hepatic, renal disease, porphyria or glucose-6-phosphate dehydrogenase deficiency. Adverse Effects: Nausea, headache, rash, loss of appetite, raised temperature. Rarely serious ADRs: Haematological: e.g. myelosuppression; Hypersensitivity: e.g. Stevens-Johnson syndrome, photosensitivity, lung complications, fever; G-I Reactions: e.g. hepatitis; CNS: e.g. neuropathy; Fertility: reversible oligospermia; Renal: e.g. proteinuria. Contraindications: Pregnancy, breastfeeding, for teratogenic or icteric hazards. Drug in breast milk should not be a risk to healthy infant. Package Quantities: 125 tablets in easy-open pack. Best NHS Cost: EN-tabs 125 (UK price) £12.75. Legal Status: Prescription Only. UK Product Licence Number: PL 0009/5007R. Product Authorisation Number (Ireland): PA107/5/2. Product Licence and Product Authorisation Holder: Pharmacia Biosystems Ltd, Davy Avenue, Knowlhill, Banbury, Oxfordshire, OX9 2EJ. Distributed in UK by: Kabi Pharmacia Ltd, Davy Avenue, Knowlhill, Banbury, Oxfordshire, OX9 2EJ. Distributed in Ireland by: C. J. Roberts for Kabi Pharmacia (Ireland) Ltd, Church Road, Dublin 12, Ireland.

References

1. Brook A, Cobelli M. *Annals of the Rheumatic Diseases* 1977; 36: 1075. 2. Van der Heide DM, et al. *Lancet* 1999; 354: 1036-1038. 3. Van der Heide DM, et al. *Lancet* 2002; 360: 1060-1065.